<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866645</url>
  </required_header>
  <id_info>
    <org_study_id>2004L03556</org_study_id>
    <secondary_id>SMHC-100</secondary_id>
    <nct_id>NCT00866645</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia</brief_title>
  <official_title>A Randomized Blind Parallel Intramuscular Haloperidol-Controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Intramuscular Levosulpiride in the Treatment of Chinese Patients With Agitation Of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Hotmed Sciences Co.,LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of Intramuscular&#xD;
      Levosulpiride in the treatment of Chinese patients with Agitation Of Schizophrenia compared&#xD;
      with Intramuscular Haloperidol by evaluating the change of PANSS-EC total scores at end of&#xD;
      study (72 hours after first dosing) from baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary Outcome Measures:&#xD;
&#xD;
      To evaluate the change of Agitation Calmness Evaluation Scale(ACES), Clinical Global&#xD;
      Impression(CGI, including CGI-S and CGI-I),PANSS total scores,Brief Psychiatric Rating&#xD;
      Scale(BPRS) total scores and every item of PANSS-EC from baseline to the end of study (Time&#xD;
      Frame: 72 hours) [ Designated as safety issue: No ]&#xD;
&#xD;
      To evaluate the change of patients' main complain, physical examination, lab and ECG tests,&#xD;
      AE、Rating Scale for Extrapyramidal Side Effect(RSESE) and Barnes Akathisia Scale(BAS)from&#xD;
      baseline to the end of study (Time Frame: 72 hours) [ Designated as safety issue: Yes ]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change of PANSS-EC total scores</measure>
    <time_frame>from baseline to the end of study(72 hours after first dosing)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of Agitation Calmness Evaluation Scale(ACES)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change of Clinical Global Impression(CGI, including CGI-S and CGI-I)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of PANSS total scores</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Brief Psychiatric Rating Scale(BPRS) total scores</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of every item of PANSS-EC</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Rating Scale for Extrapyramidal Side Effect(RSESE)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Barnes Akathisia Scale(BAS)</measure>
    <time_frame>from baseline to the end of study (72 hours after first dosing)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Agitation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular Levosulpiride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular Haloperidol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Haloperidol</intervention_name>
    <description>1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Intramuscular Haloperidol parenteral solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Levosulpiride</intervention_name>
    <description>2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Intramuscular Levosulpiride parenteral solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female Chinese inpatients(are required to stay at hospital during the study)&#xD;
             aged 18-65 years&#xD;
&#xD;
          -  Patients meeting the DSM-IV criteria for schizophrenia or schizophreniform psychosis&#xD;
&#xD;
          -  Agitated with a minimum total score of ≧ 15 on the five items of the PANSS-EC and at&#xD;
             least one individual item score of ≧ 5 or two item score of ≧ 4 using the 1-7 scoring&#xD;
             system&#xD;
&#xD;
          -  ACES≤3&#xD;
&#xD;
          -  Written informed consent provided by patients' legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigator and his/her relatives&#xD;
&#xD;
          -  Participation in another drug trial within 3 months prior enrolment into this study&#xD;
&#xD;
          -  Female patients during their pregnant and lactation period&#xD;
&#xD;
          -  Any currently severe unstable medical illness or disease would affect assessment for&#xD;
             this study, including epilepsy, angle closure glaucoma, disease of liver, kidney,&#xD;
             gastrointestinal tract, respiratory system, cardiovascular system(including Ischemic&#xD;
             Heart Disease), endocrine system, nervous system, immune or hematological system etc.&#xD;
&#xD;
          -  A significantly clinical abnormal value in ECG or lab results,ALT and AST values in&#xD;
             the liver function test exceeding two times of the upper limits of normal values, urea&#xD;
             nitrogen value arising up to 1.2 times of the upper limits of normal values,&#xD;
             creatinine or serum potassium exceeding normal values&#xD;
&#xD;
          -  With a family history of sudden death&#xD;
&#xD;
          -  Meet the DSM-IV criteria for substance abuse within 1 year prior enrolment&#xD;
&#xD;
          -  Regularly use antipsychotics(clozapine within 90 days), antidepressants, mood&#xD;
             stabilizers, anti-epileptics or prolonged-action preparations within 2 weeks prior&#xD;
             enrolment&#xD;
&#xD;
          -  Use of Electroconvulsive therapy within 30 days prior enrolment&#xD;
&#xD;
          -  Systematically use of sulpiride, levosulpiride or haloperidol therapy within 30 days&#xD;
             prior enrolment&#xD;
&#xD;
          -  History of or current neuroleptic malignant syndrome, severe EPS, significant tardive&#xD;
             dyskinesia&#xD;
&#xD;
          -  Severe suicide attempt&#xD;
&#xD;
          -  Known hypersensitivity to sulpiride, levosulpiride or haloperidol, or history of&#xD;
             severe drug hypersensitivity or hypersensitivity to more than 2 drugs&#xD;
&#xD;
          -  Use of psychotropics(except permitted drugs) within 12 hours prior enrolment&#xD;
&#xD;
          -  Known lack of efficacy to levosulpiride or haloperidol by formal treatment before&#xD;
&#xD;
          -  Organic mental disorders, including Mental retardation&#xD;
&#xD;
          -  History of psychosurgery treatment&#xD;
&#xD;
          -  Patients can not comply with study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Drug Clinical Trial Office, Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebei Mental Health Center</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Brain Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affilliated Hospital Of Kunming Medical College</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>GU, Niufan</name_title>
    <organization>Shanghai Mental Health Center</organization>
  </responsible_party>
  <keyword>Agitation</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Randomized</keyword>
  <keyword>Blind</keyword>
  <keyword>Parallel</keyword>
  <keyword>Intramuscular Haloperidol</keyword>
  <keyword>Controlled</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Intramuscular Levosulpiride</keyword>
  <keyword>Chinese</keyword>
  <keyword>PANSS-EC</keyword>
  <keyword>ACES</keyword>
  <keyword>CGI</keyword>
  <keyword>BPRS</keyword>
  <keyword>PANSS</keyword>
  <keyword>RSESE</keyword>
  <keyword>BAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

